An FDA-cleared VR headset treats back pain. The sham did almost as well

RelieVRx is a virtual-reality headset that runs an eight-week home programme of guided breathing, biofeedback and pain-education exercises, and in 2021 it became the first VR system the US Food and Drug Administration authorised as a treatment for chronic low back pain [s1]. Its trials are unusually honest about what it does: people who use it get meaningfully better, but so do people handed a dummy headset, and the slice of improvement that belongs to the therapy itself is small [s2][s3].

The device is a genuine prescription digital therapeutic, not a wellness app. It was cleared through the FDA's De Novo route — the pathway for a low-to-moderate-risk device type with no existing equivalent — under the name EaseVRx, granted to AppliedVR on 16 November 2021 for adults with a diagnosis of chronic lower back pain [s1]. That authorisation rested on real randomised evidence, which is exactly why it repays a close read.

The pivotal trial

The study behind the clearance was a double-blind, placebo-controlled randomised trial in 179 adults with self-reported chronic low back pain of at least six months and average daily pain of 4 or more out of 10 [s2]. Participants were assigned 1:1 to one of two 56-day programmes delivered through an identical commercial headset: the therapeutic EaseVRx skills programme, or a sham that played two-dimensional nature footage in the same device [s2]. Neither the participants nor the researchers knew which was which — the harder version of a control, because the sham looks and feels like the real thing.

By the end of treatment, EaseVRx was statistically superior to the sham for pain intensity and for pain-related interference with activity, mood and stress, though not sleep [s2]. A three-month follow-up reported that the advantage held, and a separate six-month analysis found the therapeutic programme stayed superior to sham for pain intensity and interference with activity, stress and sleep, with between-group effect sizes of 0.44 to 0.54 — the modest-to-moderate range [s4]. On its own terms, that is a positive trial: a self-administered, drug-free programme beat a credible placebo and the benefit lasted.

The bigger, blunter number

What the pivotal trial could not settle is how large that benefit is in the real world, and a much larger study answered it uncomfortably. A sham-controlled effectiveness trial enrolled 1,067 demographically diverse adults with clinically severe chronic low back pain and randomised them 1:1 to RelieVRx or an active sham headset [s3]. Both groups improved substantially. People using RelieVRx saw their pain intensity fall by about 2.0 points on the 0–10 scale by day 56 (95% CI 1.73–2.06), a clinically meaningful drop [s3]. But the sham group improved too, and the difference between the two — the part attributable to the therapy rather than to attention, expectation and simply doing something daily — was 0.406 points for pain intensity (95% CI 0.170–0.642) and 0.523 for pain interference (0.285–0.760) [s3]. Statistically real; clinically slim.

That is the whole tension of the category in one dataset. The headline experience for a user — pain down two points — is largely shared with the placebo. The value the device adds on top is genuine but small, and a reader deciding whether it is worth the cost and effort should weigh the 0.4, not the 2.0.

Why the placebo is the story

Chronic pain is one of the most placebo-responsive conditions in medicine, which is why the sham-headset design matters so much and why softer studies of pain apps that lack one tend to overstate their products. RelieVRx's own developers built strong shams and published the gap anyway — an approach that puts its evidence well ahead of most of the hundreds of digital therapeutics now cleared across several countries, where effect sizes are rarely comparable and often thin. It sits alongside the broader lesson that FDA clearance certifies a bar was cleared, not that a product is potent — and that the category's real obstacle has been getting anyone to pay for it, and the recurring finding that what actually helps inside a mental-health or behavioural app is often the structure and engagement, not the novel technology. UK appraisers have made the same point about where the evidence for digital mental-health tools is still missing.

Why it matters

A drug-free, non-addictive, home-based option for a condition often managed with opioids is worth having, and a 0.4-point average masks the possibility that some people respond much more than others [s3]. The case for RelieVRx is not that it is powerful; it is that it is safe, self-administered and modestly better than a convincing placebo, on better evidence than most of its peers [s2][s3][s4]. The case against overselling it is in the same numbers.

What to watch

Whether trials can identify who the strong responders are, so the therapy can be aimed rather than broadcast; whether the effect survives outside a study, once the novelty of a headset wears off; and whether payers treat a small-but-real controlled benefit as worth reimbursing when the sham did most of the visible work.

This article is informational and is not medical advice.

Sources

• [s1] "De Novo classification DEN210014: EaseVRx." U.S. Food and Drug Administration, decision 16 November 2021. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN210014
• [s2] Garcia LM, Birckhead BJ, Krishnamurthy P, et al. "An 8-Week Self-Administered At-Home Behavioral Skills-Based Virtual Reality Program for Chronic Low Back Pain: Double-Blind, Randomized, Placebo-Controlled Trial Conducted During COVID-19." Journal of Medical Internet Research, 23(2):e26292, 22 February 2021. https://doi.org/10.2196/26292
• [s3] Maddox T, Oldstone L, Sparks CY, et al. "In-Home Virtual Reality Program for Chronic Lower Back Pain: A Randomized Sham-Controlled Effectiveness Trial in a Clinically Severe and Diverse Sample." Mayo Clinic Proceedings Digital Health, 1(4):563–573, 24 October 2023. https://doi.org/10.1016/j.mcpdig.2023.09.003
• [s4] Garcia LM, Birckhead BJ, Krishnamurthy P, et al. "Durability of the Treatment Effects of an 8-Week Self-administered Home-Based Virtual Reality Program for Chronic Low Back Pain: 6-Month Follow-up Study of a Randomized Clinical Trial." Journal of Medical Internet Research, 24(5):e37480, 25 May 2022. https://doi.org/10.2196/37480